A historical literature review of coronary microvascular obstruction and intra-myocardial hemorrhage as functional/structural phenomena
作者机构:Laboratory of Experimental CardiologyCardiology Research InstituteTomsk National Research Medical Center of the Russian Academy of SciencesTomskTomsk Region 634012Russia Department of Physiology and PathophysiologyNational Key Discipline of Cell BiologySchool of Basic Medicinethe Fourth Military Medical UniversityXi'anShaanxi 710032China Siberian State Medical UniversityTomskTomsk Region 634050Russia National Center of Cardiology and Internal MedicineBishkek 720040Kyrgyzstan.
出 版 物:《The Journal of Biomedical Research》 (生物医学研究杂志(英文版))
年 卷 期:2023年第37卷第4期
页 面:268-289页
核心收录:
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金:supported by the Russian Science Foundation(Grant No.23-65-10017) The mini-chapter on treatment of MVO was supported by state assignment 122020300042-4
主 题:heart ischemia reperfusion microvascular obstruction intra-myocardial hemorrhage
摘 要:The analysis of experimental data demonstrates that platelets and neutrophils are involved in the no-reflow phenomenon,also known as microvascular obstruction(MVO).However,studies performed in the isolated perfused hearts subjected to ischemia/reperfusion(I/R)do not suggest the involvement of microembolization and microthrombi in this *** intracoronary administration of alteplase has been found to have no effect on the occurrence of MVO in patients with acute myocardial ***,the major events preceding the appearance of MVO in coronary arteries are independent of microthrombi,platelets,and *** cells appear to be the target where ischemia can disrupt the endothelium-dependent vasodilation of coronary ***,reperfusion triggers more pronounced damage,possibly mediated by *** and intra-myocardial hemorrhage contribute to the adverse post-infarction myocardial ***,pharmacological agents used to treat MVO should prevent endothelial injury and induce relaxation of smooth *** conditioning protocols have been shown to prevent MVO,with L-type Ca2+channel blockers appearing the most effective in treating MVO.